Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 3/20 | 0.58 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.58 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.58 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.58 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.58 |
| ▸ | KIF11 | P52732 | 1/20 | 0.55 |
| ▸ | OTUD7B | Q6GQQ9 | 3/20 | 0.54 |
| ▸ | PGR | P06401 | 8/20 | 0.53 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.50 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3306017 | 0.87 | KIF11 (0.62) | CYP11B1CYP11B2CYP1A2CYP2C9TBXAS1 | |
| SCHEMBL2015376 | 0.84 | NPC1 (0.50) | CYP11B1CYP11B2CYP1A2CYP2C9TBXAS1 | |
| SCHEMBL30100790 | 0.84 | NPC1 (0.50) | CYP11B1CYP11B2CYP1A2CYP2C9TBXAS1 | |
| SCHEMBL3306566 | 0.81 | KIF11 (0.69) | CYP11B1CYP11B2CYP1A2CYP2C9TBXAS1 | |
| SCHEMBL29533407 | 0.78 | CYP11B1 (0.62) | CYP11B1CYP11B2CYP1A2CYP2C9TBXAS1 | |
| SCHEMBL3309677 | 0.78 | KIF11 (0.62) | CYP11B1CYP11B2CYP1A2CYP2C9TBXAS1 | |
| SCHEMBL13525229 | 0.78 | CYP11B1 (0.62) | CYP11B1CYP11B2CYP1A2CYP2C9TBXAS1 | |
| SCHEMBL3307911 | 0.78 | KIF11 (0.58) | CYP11B1CYP11B2CYP1A2CYP2C9TBXAS1 | |
| SCHEMBL4596356 | 0.77 | KIF11 (0.57) | CYP11B1CYP11B2CYP1A2CYP2C9TBXAS1 | |
| SCHEMBL4423216 | 0.75 | PGR (0.56) | CYP11B1CYP11B2CYP1A2PGRCHEK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8952007-B2 | Fused heterocyclic compounds as ion channel modulators | GILEAD SCIENCES, INC. (US) | 2015-02-10 | — | — | US | claimed |
| US-20130096122-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | GILEAD SCIENCES, INC. (US) | 2013-04-18 | — | — | US | claimed |
| WO-2010074807-A1 | 3, 4-DIHYDROQUINOLIN-2 ( 1H ) -ONE DERIVATIVES AS SODIUM CHANNEL MODULATORS | GILEAD PALO ALTO, INC. (US) | 2010-07-01 | — | — | WO | claimed |
| US-20100113514-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | GILEAD PALO ALTO, INC. (US) | 2010-05-06 | — | — | US | claimed |
| US-8952007-B2 | Fused heterocyclic compounds as ion channel modulators | GILEAD SCIENCES, INC. (US) | 2015-02-10 | — | — | US | disclosed |
| US-8664379-B2 | Fused heterocyclic compounds as ion channel modulators | GILEAD SCIENCES, INC. (US) | 2014-03-04 | — | — | US | disclosed |
| US-20130096122-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | GILEAD SCIENCES, INC. (US) | 2013-04-18 | — | — | US | disclosed |
| WO-2010074807-A1 | 3, 4-DIHYDROQUINOLIN-2 ( 1H ) -ONE DERIVATIVES AS SODIUM CHANNEL MODULATORS | GILEAD PALO ALTO, INC. (US) | 2010-07-01 | — | — | WO | disclosed |
| US-20100113514-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | GILEAD PALO ALTO, INC. (US) | 2010-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113514-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | KCNJ2, KCNH2, KCNH3 | CYP11B1 1655/4885CYP11B2 1716/4885CYP1A2 2073/4885 |
| US-20130096122-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | KCNJ2, KCNH2, CACNA1E | CYP11B1 1355/4885CYP11B2 1629/4885CYP1A2 1928/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.